Vicus Therapeutics Announces Phase II Data Demonstrating Overall Survival Benefit with VT-122 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

MORRISTOWN, N.J (PRWEB) September 05, 2014 Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, announced positive results from a Phase II randomized, open-label, controlled clinical trial of its lead compound, VT-122, in combination with sorafenib, in patients with advanced hepatocellular carcinoma (HCC). In an intent-to-treat (ITT) population, investigators […]

Ebola Outbreak : Survival Medicine with Dr. Bones

The Ebola virus outbreak in West Africa is explained by Joe Alton, M.D., aka Dr. Bones. Symptoms, transmission, prevention and death rate of Ebola virus infe… The Fratellis third abum “We Need Medicine” released 7th October 2013, available to buy on iTunes, all good music stores and well…anywhere I guess. Check o… Video Rating: 4 […]